Investment analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Monday. The firm set a "sell" rating on the biotechnology company's stock.
A number of other research analysts have also weighed in on the company. HC Wainwright lowered Genocea Biosciences from a "buy" rating to a "neutral" rating in a report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a report on Friday, April 29th. Finally, Robert W. Baird cut their price objective on Genocea Biosciences from $8.00 to $3.00 in a report on Monday, April 11th.
Get
Genocea Biosciences alerts:
Genocea Biosciences Trading Down 6.7 %
Shares of NASDAQ:GNCA opened at $0.01 on Monday. The business's 50-day moving average is $0.03 and its 200 day moving average is $0.56. Genocea Biosciences has a 1 year low of $0.01 and a 1 year high of $2.20. The firm has a market capitalization of $657,820.80, a P/E ratio of -0.02 and a beta of 2.26. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.
Insider Buying and Selling
In related news, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total transaction of $355,607.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, major shareholder Paul Edward Walker sold 5,931,843 shares of the firm's stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $0.07, for a total transaction of $415,229.01. Following the sale, the insider now directly owns 4,445,093 shares of the company's stock, valued at $311,156.51. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The disclosure for this sale can be found here. Insiders have sold a total of 10,537,612 shares of company stock valued at $781,461 over the last ninety days. Company insiders own 1.61% of the company's stock.
Institutional Trading of Genocea Biosciences
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its holdings in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 59.25% of the company's stock.
Genocea Biosciences Company Profile
(Get Rating)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Recommended Stories
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Use These To Find Your Stock's Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter's Up For Third Week In A Row: What's Next For The Stock?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
